Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination

被引:62
作者
Jokinen, Sari [1 ]
Osterlund, Pamela [1 ]
Julkunen, Ilkka [1 ]
Davidkin, Irja [1 ]
机构
[1] Natl Publ Hlth Inst, Dept Viral Dis & Immunol, SF-00300 Helsinki, Finland
关键词
D O I
10.1086/521029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Measles-mumps-rubella (MMR) vaccination has decreased the incidence of measles, Mumps, and rubella virus infections in several countries. However, the persistence of MMR vaccine-induced immunity in the absence of endemic infection has remained unknown. Methods. The persistence of cellular and Immoral immunity to mumps virus was studied in 50 individuals (group A) who had been vaccinated twice with MMR vaccine during early childhood and were followed up for 21 years after their first vaccination. Eleven individuals (group B) with naturally acquired immunity to mumps virus were studied for comparison. Results. Anti-mumps virus IgG antibodies were detectable (titer >= 230) in 72% of the vaccinces. A mumps antigen-specific lymphoproliferative response (defined as a stimulatory index [SI] >= 3) was observed in 98% of group A subjects (mean +/- SD SI, 26 +/- 30 [range, 0.5-252]) and in 100% of group B subjects (mean +/- SD SI, 22 27 [range, 5-123]). Significant mumps antigen-specific interferon-gamma production was detected in 73% of subjects in both groups A and B, and interleukin-10 production was detected in 40% and 36% of group A and B subjects, respectively. Conclusions. All presently seronegative vaccinees (n = 14) had mumps antigen-specific lymphoproliferative responses, and only I of the seropositive vaccinees (n = 36) was devoid of detectable cellular immunity. The results suggest a very long persistence of vaccine-induced anti-mumps virus cellular immunity.
引用
收藏
页码:861 / 867
页数:7
相关论文
共 30 条
[1]   Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme [J].
Broliden, K ;
Abreu, ER ;
Arneborn, M ;
Böttiger, M .
VACCINE, 1998, 16 (2-3) :323-327
[2]  
CACKHOUSE J, 2006, CLIN VACCINE IMMUNOL, V13, P764
[3]   METHODS FOR SCREENING THE NATURALLY ACQUIRED AND VACCINE-INDUCED IMMUNITY TO THE MUMPS-VIRUS [J].
CHRISTENSON, B ;
BOTTIGER, M .
BIOLOGICALS, 1990, 18 (03) :213-219
[4]  
Crowley B, 2002, Commun Dis Public Health, V5, P311
[5]   PERSISTENCE OF ANTI-MUMPS VIRUS-ANTIBODIES AFTER A 2 DOSE MMR VACCINATION - A 9-YEAR FOLLOW-UP [J].
DAVIDKIN, I ;
VALLE, M ;
JULKUNEN, I .
VACCINE, 1995, 13 (16) :1617-1622
[6]   Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella [J].
Davidkin, I ;
Jokinen, S ;
Paananen, A ;
Leinikki, P ;
Peltola, H .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05) :719-723
[7]   Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children [J].
Dhiman, N ;
Ovsyannikova, IG ;
Jacobson, RM ;
Vierkant, RA ;
Pankratz, VS ;
Jacobsen, SJ ;
Poland, GA .
CLINICAL IMMUNOLOGY, 2005, 115 (02) :154-161
[8]  
DING YZ, 2003, CYTOKINE HDB, V1, P603
[9]   Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12-to 24-month-old children [J].
Feiterna-Sperling, C ;
Brönnimann, R ;
Tischer, A ;
Stettler, P ;
Durrer, P ;
Gaedicke, G .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (12) :1083-1088
[10]   Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months [J].
Gans, H ;
Yasukawa, L ;
Rinki, M ;
DeHovitz, R ;
Forghani, B ;
Beeler, J ;
Audet, S ;
Maldonado, Y ;
Arvin, AM .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (07) :817-826